Asia-Pacific Minimally Invasive Surgery Devices Market Size

APAC Minimally Invasive Devices Market Analysis

The Asia-Pacific minimally invasive surgery devices market is expected to register a CAGR of 7.1% during the forecast period.

The COVID-19 pandemic has had an impact on a variety of surgical techniques, including minimally invasive ones. Due to the strict restrictions, patients with various lifestyle-related and chronic diseases experienced a delay in diagnosis and treatment due to fewer hospital visits which hampered the market studied. According to the January 2022 published study in the JMAS, overall elective operations and minimally invasive surgery (MIS) were reduced proportionally in India. Across the country, most surgeons reported a drop in overall elective surgical volume (93.2%) and MIS cases (88.4%). There was a corresponding decline in laparoscopic, thoracoscopic, and robotic cases among MIS cases across the country. As a result, in the early stages of the outbreak, COVID-19 harmed market growth. However, since the restrictions were lifted, the industry has recovered well. Over the last two years, the market recovery has been led by the high prevalence of diseases, new product launches, and increased demand for minimally invasive surgeries.

The major factors for the growth of the Asia-Pacific minimally invasive surgery devices market include the increasing prevalence of lifestyle-related and chronic disorders and technological advancements. Alterations in metabolic activity and lifestyle changes are linked to cardiovascular risk, and the rising incidence of cardiovascular diseases is expected to propel the growth of the market. According to the article published in a White paper in May 2022, atherosclerotic cardiovascular disease (ASCVD) resulted in significant productivity loss in the Asia-Pacific region, including several countries such as Vietnam.

Cancer cases are also rising across the Asia-Pacific region, along with the demand for minimally invasive surgeries, which is expected to boost the demand for MIS devices. For instance, as per the Globocan 2020 statistics, the estimated number of new cancer cases was 9,503,710, and the number of prevalent cases (5 years) was 20,606,063 in the Asia-Pacific region in 2020. Among these, new cases of lung cancer were the highest, with 1,315,136 (13.8%) cases, followed by breast cancer cases at 1,026,171 (10.8%) in 2020. Thus, the high burden of cancer is expected to boost the demand for MIS devices during the forecast period.

Furthermore, there are various advantages of MIS over other surgeries, which are also likely to support market expansion. Minimally invasive surgeries (MIS) cause less post-operative pain, and patients receive smaller dosages of painkillers. As there are minimal cuts or stitches involved, the hospital stay is relatively short, and patients need not visit the hospital frequently. In addition, minimally invasive surgeries (MIS) provide a more detailed and magnified image of the organs or body parts operated on and increased precision due to video-assisted technology.

Moreover, various strategies adopted by key market players, such as product launches, mergers and acquisitions, and partnerships, are expected to support market growth. For instance, in June 2021, Pentax Medical formed a new joint venture (JV) with Jiangsu Vedkang Medical Science and Technology (Vedkang) to develop endoscopic therapies. Therapeutic devices and flexible medical endoscopes are used in minimally invasive procedures to benefit patients, physicians, and healthcare systems by dramatically reducing procedure cost/complexity and improving patient recovery time. As a result of the advantages associated with minimally invasive operations, the market is likely to expand during the forecast period.

However, a shortage of experienced professionals may restrain the market growth.